While Novavax"s clinical trials were underway, new variants of Covid-19 began to emerge, enabling them to prove that their vaccine was still effective against a range of different strains. So far, its data shows that their vaccine is 93% effective against the Alpha and Beta variants, although no efficacy has been published for the dominant Delta strain and it is still too early to say if it will be effective against Omicron.